Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Liufang Gu
Observed names:
Gu Liu-Fang,
LIU-FANG GU,
Liu-Fang Gu
Institutions:
Second Affiliated Hospital of Xi'an Jiaotong University,
Xi'an Jiaotong University
Observed institutions:
Second Affiliated Hospital of Xi'an Jiaotong University,
Xi'an Jiaotong University
OpenAlex ID:
A5113066397
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
2018
·
Wan-Hong Zhao
, Jie Liu
, et al.
·
Journal of Hematology & Oncology
·
518
PDF
Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)
2022
·
Wan-Hong Zhao
, Bai-Yan Wang
, et al.
·
Journal of Hematology & Oncology
·
141
PDF
Management of cytokine release syndrome related to CAR-T cell therapy
2019
·
Hongli Chen
, Fangxia Wang
, et al.
·
Frontiers of Medicine
·
107
Long-Term Follow-up of a Phase 1, First-in-Human Open-Label Study of LCAR-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (BCMA), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
2019
·
Bai-Yan Wang
, Wan-Hong Zhao
, et al.
·
Blood
·
88
Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma.
2017
·
Frank (Xiaohu) Fan
, Wanhong Zhao
, et al.
·
Journal of Clinical Oncology
·
81
Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma.
2017
·
Frank (Xiaohu) Fan
, Wanhong Zhao
, et al.
·
Journal of Clinical Oncology
·
66
Expression profile analysis of long non‐coding RNA in acute myeloid leukemia by microarray and bioinformatics
2017
·
Yuandong Feng
, Ying Shen
, et al.
·
Cancer Science
·
45
Updated Analysis of a Phase 1, Open-Label Study of LCAR-B38M, a Chimeric Antigen Receptor T Cell Therapy Directed Against B-Cell Maturation Antigen, in Patients with Relapsed/Refractory Multiple Myeloma
2018
·
Wan-Hong Zhao
, Jie Liu
, et al.
·
Blood
·
37
Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia
2010
·
Liu-Fang Gu
, Wang-Gang Zhang
, et al.
·
Journal of Cancer Research and Clinical Oncology
·
28
Chimeric Antigen Receptor T Cell Therapy in the Relapsed or Refractory Multiple Myeloma with Extramedullary Disease--a Single Institution Observation in China
2020
·
Baiyan Wang
, Jie Liu
, et al.
·
Blood
·
23
Quantitative assessment of MLAA-34 expression in diagnosis and prognosis of acute monocytic leukemia
2011
·
Jianqiang Zhao
, Aili He
, et al.
·
Cancer Immunology Immunotherapy
·
13
Effects of CpG oligodeoxynucleotides on the differentiation of Treg/Th17 cells
2021
·
Hailing Liu
, Yuqiang Ji
, et al.
·
Molecular Immunology
·
12
Investigation of a novel biomarker, neuropilin-1, and its application for poor prognosis in acute myeloid leukemia patients
2014
·
Jianqiang Zhao
, Liufang Gu
, et al.
·
Tumor Biology
·
10
Pellino-1 Protects Periodontal Ligament Stem Cells Against H2O2-Induced Apoptosis via Activation of NF-κB Signaling
2018
·
Jiangang Tian
, Liufang Gu
, et al.
·
Molecular Biotechnology
·
9
The expression and functional characterization associated with cell apoptosis and proteomic analysis of the novel gene MLAA-34 in U937 cells
2012
·
WEN-JUAN ZHANG
, WANG-GANG ZHANG
, et al.
·
Oncology Reports
·
9
PDF
Inhibition of WNT7A-β-catenin signaling pathway sensitizes oral squamous cell carcinoma to cisplatin.
2018
·
Jiangang Tian
, Xiaoguang Cui
, et al.
·
PubMed
·
8
Effect of granulocyte colony-stimulating factor priming combined with low-dose cytarabine and homoharringtonine in higher risk myelodysplastic syndrome patients
2016
·
Fang-Xia Wang
, Wang-Gang Zhang
, et al.
·
Leukemia Research
·
6
Five-year remission without disease progression in a patient with relapsed/refractory multiple myeloma with extramedullary disease treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study: a case report
2022
·
Bai-Yan Wang
, Wan-Hong Zhao
, et al.
·
Journal of Medical Case Reports
·
5
PDF
Dose-enhanced combined priming regimens for refractory acute myeloid leukemia and middle-and-high-risk myelodysplastic syndrome: a single-center, retrospective cohort study
2016
·
Xiaorong Ma
, Jin Wang
, et al.
·
OncoTargets and Therapy
·
4
PDF
Prediction and identification of HLA-A*0201-restricted epitopes from leukemia-associated protein MLAA-22 which elicit cytotoxic T lymphocytes
2014
·
Jing Li
, Ju Bai
, et al.
·
Medical Oncology
·
3
[Drug-Resistant Mechanism of Multiple Myeloma and Its Therapy Combined with HDACi -Review].
2017
·
Liu-Fang Gu
, Xiao-Guang Cui
, et al.
·
PubMed
·
2
Extended Course and Increased Dose of Initial Chemotherapy for Extranodal Nasal Type Natural Killer/T (NK/T)-Cell Lymphoma in Patients <60 Years Old: A Single-Center Retrospective Cohort Study
2016
·
Yan Xu
, Jin Wang
, et al.
·
Medical Science Monitor
·
2
PDF
[Cohort Study on GHA and New Combined Priming Chemotherapeutic Regimens in Treatment of Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome].
2015
·
Xiao-Rong Ma
, Jin Wang
, et al.
·
PubMed
·
2
mRNA expression of the XAGE-1 gene in human acute leukemia
2010
·
Yuqiang Ji
, Wanggang Zhang
, et al.
·
International Journal of Hematology
·
2
MLAA-34: A New Leukemia-Associated Antigen for Immunotherapy Against Acute Monocytic Leukemia
2014
·
Ju Bai
, Aili He
, et al.
·
Blood
·
1
Show more works
View as search
Works count:
40
Citation count:
1,223
H-index:
12
I10-index:
13
Year
Topic
Type
